Kristin J Skaarud1, Marianne J Hjermstad2, Asta Bye3, Marit B Veierød4, Anne M Gudmundstuen5, Knut E A Lundin6, Sonia Distante7, Lorentz Brinch8, Geir E Tjønnfjord9, Per O Iversen10. 1. Department of Haematology, Oslo University Hospital, Norway; Department of Nutrition, Institute of Basic Medical Sciences, University of Oslo, Norway. 2. European Palliative Care Research Centre, Department of Oncology, Oslo University Hospital and Institute of Clinical Medicine, University of Oslo, Oslo, Norway. 3. European Palliative Care Research Centre, Department of Oncology, Oslo University Hospital and Institute of Clinical Medicine, University of Oslo, Oslo, Norway; Department of Nursing and Health Promotion, Faculty of Health Sciences, Oslo Metropolitan University, Oslo, Norway. 4. Oslo Centre for Biostatistics and Epidemiology, Department of Biostatistics, Institute of Basic Medical Sciences, University of Oslo, Norway. 5. Department of Haematology, Oslo University Hospital, Norway; Institute of Clinical Medicine, University of Oslo, Norway. 6. Institute of Clinical Medicine, University of Oslo, Norway; Department of Gastroenterology, Oslo University Hospital, Norway; K.G. Jebsen Centre for Coeliac Disease Research, University of Oslo, Norway. 7. Department of Medical Biochemistry, Oslo University Hospital, Norway. 8. Department of Haematology, Oslo University Hospital, Norway. 9. Department of Haematology, Oslo University Hospital, Norway; Institute of Clinical Medicine, University of Oslo, Norway; K.G. Jebsen Centre for B Cell Malignancies, University of Oslo, Norway. 10. Department of Haematology, Oslo University Hospital, Norway; Department of Nutrition, Institute of Basic Medical Sciences, University of Oslo, Norway. Electronic address: poiversen@hotmail.com.
Abstract
BACKGROUND & AIMS: Reduced quality of life (QoL) is prevalent after allogeneic hematopoietic stem cell transplantation (allo-HSCT). In this randomized trial we examined the effect of individualized nutritional support during hospitalization for allo-HSCT. Primary outcome was change in global QoL three months post-HSCT with oral mucositis (OM) and acute graft-versus-host disease (aGVHD) as main secondary outcomes. METHODS: Whereas the intervention group received recommended minimum daily intakes of 126 kJ/kg and 1.5-2.0 g protein/kg as food, supplements, enteral or parenteral nutrition, the controls received routine feeding. QoL was self-reported using the EORTC QLQ-C30 questionnaire. RESULTS: Between August, 2010 and February, 2016, we randomized 59 and 60 patients to intervention and control, respectively; 40 and 48 being eligible for analysis of QoL. There was no difference between the two groups in mean global QoL after three months (-3.10, 95% CI -11.90-5.69; P = 0.49). Nor were there any differences in OM grades 3 or 4 (RR (vs grades 0-2), 1.11, 95% CI 0.59-2.11 and 0.95, 95% CI 0.72-1.25, respectively; P = 0.78), or aGVHD grades 3 or 4 (RR (vs grades 0-2) 0.44, 95% CI 0.12-1.60; and 0.65, 95% CI 0.20-2.20, respectively; P = 0.37). CONCLUSION:Individualized nutritional support with recommended energy and protein intakes during hospitalization had no effect on QoL, OM or aGVHD three months after allo-HSCT compared to routine nutrition.
RCT Entities:
BACKGROUND & AIMS: Reduced quality of life (QoL) is prevalent after allogeneic hematopoietic stem cell transplantation (allo-HSCT). In this randomized trial we examined the effect of individualized nutritional support during hospitalization for allo-HSCT. Primary outcome was change in global QoL three months post-HSCT with oral mucositis (OM) and acute graft-versus-host disease (aGVHD) as main secondary outcomes. METHODS: Whereas the intervention group received recommended minimum daily intakes of 126 kJ/kg and 1.5-2.0 g protein/kg as food, supplements, enteral or parenteral nutrition, the controls received routine feeding. QoL was self-reported using the EORTC QLQ-C30 questionnaire. RESULTS: Between August, 2010 and February, 2016, we randomized 59 and 60 patients to intervention and control, respectively; 40 and 48 being eligible for analysis of QoL. There was no difference between the two groups in mean global QoL after three months (-3.10, 95% CI -11.90-5.69; P = 0.49). Nor were there any differences in OM grades 3 or 4 (RR (vs grades 0-2), 1.11, 95% CI 0.59-2.11 and 0.95, 95% CI 0.72-1.25, respectively; P = 0.78), or aGVHD grades 3 or 4 (RR (vs grades 0-2) 0.44, 95% CI 0.12-1.60; and 0.65, 95% CI 0.20-2.20, respectively; P = 0.37). CONCLUSION: Individualized nutritional support with recommended energy and protein intakes during hospitalization had no effect on QoL, OM or aGVHD three months after allo-HSCT compared to routine nutrition.
Authors: Christine Baldwin; Marian Ae de van der Schueren; Hinke M Kruizenga; Christine Elizabeth Weekes Journal: Cochrane Database Syst Rev Date: 2021-12-21
Authors: K J Skaarud; M B Veierød; S Lergenmuller; A Bye; P O Iversen; G E Tjønnfjord Journal: Bone Marrow Transplant Date: 2019-08-27 Impact factor: 5.483
Authors: Kristin J Skaarud; Johannes R Hov; Simen H Hansen; Martin Kummen; Jørgen Valeur; Ingebjørg Seljeflot; Asta Bye; Vemund Paulsen; Knut E A Lundin; Marius Trøseid; Geir E Tjønnfjord; Per Ole Iversen Journal: Sci Rep Date: 2021-06-02 Impact factor: 4.379